Generali Asset Management SPA SGR Has $5.93 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• Generali Asset Management SPA SGR increased its stake in IQVIA Holdings Inc. by 30% in the second quarter, now owning 37,624 shares valued at $5.93 million.
• IQVIA reported a quarterly earnings per share of $2.81, surpassing analysts' expectations, with a revenue of $4.02 billion, marking a 5.3% year-over-year increase.
• Analyst ratings for IQVIA show a consensus target price of $234.57 with the vast majority of analysts recommending a buy, including recent price upgrades from UBS and Mizuho.

Generali Asset Management SPA SGR boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 30.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,624 shares of the medical research company's stock after acquiring an additional 8,689 shares during the quarter. Generali Asset Management SPA SGR's holdings in IQVIA were worth $5,929,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd increased its position in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the first quarter worth approximately $33,000. Trust Co. of Toledo NA OH acquired a new stake in shares of IQVIA during the second quarter worth approximately $39,000. Finally, J.Safra Asset Management Corp increased its holdings in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company's stock worth $39,000 after buying an additional 169 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Price Performance

IQV opened at $203.38 on Thursday. The company has a fifty day moving average price of $190.38 and a two-hundred day moving average price of $168.79. The firm has a market capitalization of $34.58 billion, a PE ratio of 29.43, a P/E/G ratio of 2.25 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.21.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. UBS Group raised their price target on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Mizuho raised their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Weiss Ratings restated a "hold (c)" rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Robert W. Baird raised their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.